Research & Development
MaaT Pharma receives negative CHMP trend vote for MaaT013
15 September 2026 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) disclosed on Tuesday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
15 September 2026 - Cure SMA, a nonprofit organisation supporting those impacted by spinal muscular atrophy (SMA), on Monday welcomed the announcement by biopharmaceutical company Scholar Rock (NASDAQ...
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
14 September 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) said on Monday that the US Food and Drug Administration (FDA) has accepted its new drug application for zasocitinib (TA...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation fo...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1...
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
14 September 2026 - Eloxx Pharmaceuticals Inc (Nasdaq:ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, announced on Friday that the firs...